<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144417</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHSTP-4448</org_study_id>
    <nct_id>NCT00144417</nct_id>
  </id_info>
  <brief_title>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</brief_title>
  <official_title>TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in&#xD;
      daily treatment during the first two months of treatment with rifampin, pyrazinamide and&#xD;
      ethambutol for sputum smear-positive pulmonary tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this Phase 2 clinical trial is to compare the safety and&#xD;
      antimicrobial activity of a moxifloxacin-containing regimen (moxifloxacin, rifampin,&#xD;
      pyrazinamide, ethambutol [MRZE]) in which moxifloxacin has been substituted for isoniazid, to&#xD;
      the standard control regimen (isoniazid, rifampin, pyrazinamide, ethambutol [HRZE]) in the&#xD;
      first two months of treatment of sputum smear-positive pulmonary tuberculosis. The assessment&#xD;
      of antimicrobial activity will be sputum culture-conversion. Higher rates of sputum culture&#xD;
      conversion after 2 months of treatment with a moxifloxacin-containing regimen would support&#xD;
      Phase 3 clinical trials of moxifloxacin in treatment regimens of less than the current 6&#xD;
      month standard regimens.&#xD;
&#xD;
      Rationale - Current treatment of smear positive pulmonary tuberculosis requires a minimum of&#xD;
      6 months, a treatment duration that is challenging for patients and tuberculosis control&#xD;
      programs. Therefore, a high priority in tuberculosis research is the identification of agents&#xD;
      that can shorten treatment. Several fluoroquinolone antibiotics have potent activity against&#xD;
      Mycobacterium tuberculosis (M. tuberculosis) in preclinical testing. Of the currently&#xD;
      available fluoroquinolones, moxifloxacin has excellent activity in vitro and in animal models&#xD;
      of tuberculosis, a favorable pharmacokinetic profile (serum half-life of 10-12 hours), lack&#xD;
      of problematic drug-drug interactions, no need for dosage adjustment for renal and hepatic&#xD;
      insufficiency, and an excellent safety profile. In addition, in the murine model of&#xD;
      tuberculosis, the substitution of moxifloxacin for isoniazid resulted in significant&#xD;
      reductions in the time to culture conversion and the time to sterilization when compared to&#xD;
      the standard combination rifampin, isoniazid and pyrazinamide. However, moxifloxacin has not&#xD;
      been fully evaluated in humans for tuberculosis treatment. There is a need to assess not only&#xD;
      the anti-tuberculosis activity of moxifloxacin-containing regimens, but also the safety of&#xD;
      more prolonged therapy with moxifloxacin.&#xD;
&#xD;
      Two-month culture conversion rates are a well-accepted surrogate marker for the sterilizing&#xD;
      activity of anti-tuberculosis drugs. Rifampin and pyrazinamide, the key drugs in current&#xD;
      6-month regimens, markedly increase 2-month culture-conversion rates. Therefore, this study&#xD;
      will use 2-month culture conversion rate as the measure of antimicrobial activity of&#xD;
      moxifloxacin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimen</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the safety and tolerability of the moxifloxacin regimen to that of the isoniazid regimen</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to culture-conversion of the moxifloxacin regimen and the isoniazid regimen using data from 2-, 4-, 6-, and 8-week cultures</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the proportion of patients with any Grade 3 or 4 adverse reactions</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the rates of treatment failure of the moxifloxacin regimen and the isoniazid regimen</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether there is delayed toxicity attributable to moxifloxacin (toxicity that becomes evident after the 8 weeks of moxifloxacin therapy)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">433</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>HRZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRZE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)</intervention_name>
    <description>Moxifloxacin 400mg daily, 8 weeks</description>
    <arm_group_label>MRZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazid</intervention_name>
    <description>isoniazid, oral, 300 mg, daily, 8 weeks</description>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of&#xD;
             expectorated or induced sputum. Patients whose sputum cultures do not grow M.&#xD;
             tuberculosis and those having an M. tuberculosis isolate resistant to (one or more)&#xD;
             isoniazid, rifampin, fluoroquinolones, will be discontinued from the study, but&#xD;
             followed for 14 days to detect late toxicities from study therapy. Patients having&#xD;
             extra-pulmonary manifestations of tuberculosis, in addition to smear-positive&#xD;
             pulmonary disease, are eligible for enrollment. Sputum must be expectorated or&#xD;
             induced; smear results from respiratory secretions obtained by bronchoalveolar lavage&#xD;
             or bronchial wash may not be used for assessment of study eligibility.&#xD;
&#xD;
          -  Willingness to have HIV testing performed, if HIV serostatus is not known or if the&#xD;
             last documented negative HIV test was more than 6 months prior to enrollment. HIV&#xD;
             testing does not need to be repeated if there is written documentation of a positive&#xD;
             test (positive ELISA and Western Blot or a plasma HIV-RNA level greater than 5000&#xD;
             copies/ml) at any time in the past.&#xD;
&#xD;
          -  7 (seven) or fewer days of multidrug therapy for tuberculosis disease in the 6 months&#xD;
             preceding enrollment.&#xD;
&#xD;
          -  7 (seven) or fewer days of fluoroquinolone therapy in the 3 months preceding&#xD;
             enrollment.&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Karnofsky score of at least 60 (requires occasional assistance but is able to care for&#xD;
             most of his/her needs; see Appendix B).&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Women with child-bearing potential must agree to practice an adequate (barrier) method&#xD;
             of birth control or to abstain from heterosexual intercourse during study therapy.&#xD;
&#xD;
          -  Laboratory parameters done at, or &lt;14 days prior to, screening:&#xD;
&#xD;
          -  Serum amino aspartate transferase (AST) activity ≤ 3 times the upper limit of normal&#xD;
&#xD;
          -  Serum total bilirubin level ≤ 2.5 times the upper limit of normal&#xD;
&#xD;
          -  Serum creatinine level ≤ 2 times the upper limit of normal&#xD;
&#xD;
          -  Complete blood count with hemoglobin level of at least 7.0 g/dL&#xD;
&#xD;
          -  Complete blood count with platelet count of at least 50,000/mm3&#xD;
&#xD;
          -  Serum potassium &gt; 3.5 meq/L&#xD;
&#xD;
          -  Negative pregnancy test (women of childbearing potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Known intolerance to any of the study drugs&#xD;
&#xD;
          -  Known allergy to any fluoroquinolone antibiotic&#xD;
&#xD;
          -  Concomitant disorders or conditions for which moxifloxacin (MXF), isoniazid (INH),&#xD;
             rifampin (RIF), pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These&#xD;
             include severe hepatic damage, acute liver disease of any cause, and acute&#xD;
             uncontrolled gouty arthritis.&#xD;
&#xD;
          -  Current or planned therapy during the intensive phase of therapy using drugs having&#xD;
             unacceptable interactions with rifampin (rifabutin can be substituted for rifampin&#xD;
             during the continuation phase of therapy).&#xD;
&#xD;
          -  Current or planned antiretroviral therapy during the intensive phase of therapy.&#xD;
&#xD;
          -  History of prolonged QT syndrome or current or planned therapy with quinidine,&#xD;
             procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine during&#xD;
             the intensive phase of therapy.&#xD;
&#xD;
          -  Pulmonary silicosis&#xD;
&#xD;
          -  Central nervous system TB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Chaisson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan E Dorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John L Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Administration Medical Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francincisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health Department</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington DC Veterans Administration Medical Center</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hines Veterans Administration Medical Center</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey School of Medicine</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hospital, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Tennessee Valley Health Care System</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Science Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Memorial Veterans Administration Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle-King County Health Department</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitario Clementino Fraga Filho</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>2194.590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnepeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson R. Mandela School of Medicine</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agencia de Salut Publica</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University Medical School</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.</citation>
    <PMID>19406981</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Stefan Goldberg</name_title>
    <organization>CHSRB/DTBE/NCHHSTP/CDC</organization>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>treatment</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

